<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268059</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ON-MEDI-575-1031</org_study_id>
    <nct_id>NCT01268059</nct_id>
  </id_info>
  <brief_title>A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose, antitumor activity, safety and
      pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with
      previously untreated, advanced non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety profile of MEDI-575 when used in combination with carboplatin/paclitaxel</measure>
    <time_frame>21 days</time_frame>
    <description>Subjects will be evaluated while receiving carboplatin/paclitaxel plus MEDI-575 to evaluate dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival of subjects following treatment</measure>
    <time_frame>126 days</time_frame>
    <description>Subjects will be randomized into two arms and receive either carboplatin/paclitaxel or carboplatin/paclitaxel plus MEDI-575.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MEDI-575 Dose Determination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/Paclitaxel/MEDI-575</intervention_name>
    <description>Subjects will receive carboplatin/paclitaxel and MEDI-575 every 21 days for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.</description>
    <arm_group_label>MEDI-575 Dose Determination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/Paclitaxel</intervention_name>
    <description>Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6 mg/mL*min) for up to 6 cycles unless there is evidence of disease progression or intolerance of study treatment.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/Paclitaxel/MEDI-575</intervention_name>
    <description>Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6mg/mL*min) plus MEDI-575 at dose determined in the Dose Determination Phase. Carboplatin/paclitaxel and MEDI-575 to be given once every 21 days as an IV infusion for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age 18 years or older (20 years or older for subjects in the Japanese cohort) at the
             time of screening

          2. Written informed consent and any locally required authorization (eg, HIPAA in the USA,
             EU Data Privacy Directive in the EU) obtained from the subject/legal representative
             prior to performing any protocol-related procedures, including screening evaluations

          3. Histologically confirmed inoperable Stage IIIB or Stage IV non-small cell lung cancer
             according to the Seventh Edition of the American Joint Committee on Cancer (AJCC)
             Tumor Node Metastases (TNM) staging system (only subjects with squamous cell carcinoma
             will be enrolled)

          4. ECOG PS of 0 or 1 (see, Appendix 2)

          5. Life expectancy of ≥ 3 months

          6. Prothrombin time elevation ≤ Grade 2 by National Cancer Institute Common Toxicity
             Criteria for Adverse Events (NCI CTCAE) criteria (Version 4.0) is acceptable for
             subjects on anticoagulant therapy

          7. Adequate hematologic function defined as:

          8. Hemoglobin ≥ 9 g/dL

          9. Absolute neutrophil count (ANC) ≥ 1500/mm3

         10. Platelet count ≥ 100,000/mm3

         11. Adequate organ function defined as follows:

         12. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

             ≤ 5 × institutional upper limit of normal (ULN) for cases involving liver metastasis
             and ≤ 2 × institutional ULN for all other cases

         13. Bilirubin ≤ 1.5 × ULN except in the case of subjects with documented or suspected
             Gilbert's disease ≤ 5 × ULN

         14. Calculated creatinine clearance (CrCl) ≥ 50 mL/min as determined by the Cockroft-Gault
             equation (Cockroft and Gault, 1976)

         15. Suitable candidates for therapy with carboplatin/paclitaxel

         16. Subjects must have at least 1 lesion that is measurable using RECIST (v1.1). Other
             nonmeasurable lesions are allowed.

         17. Subjects must be willing to consent to allow collection of archived NSCLC tumor
             samples

         18. Negative serum beta-human chorionic gonadotropin (β-hCG) test (women of childbearing
             potential only)

         19. Females of childbearing potential, unless surgically sterile (ie, bilateral tubal
             ligation, bilateral oophorectomy, or complete hysterectomy), has a sterile male
             partner, is premenarchal or at least 2 years postmenopausal, or practices abstinence,
             must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or
             implanted contraceptives, intrauterine device, female condom with spermicide,
             diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the
             sexual partner) from screening, and must agree to continue using such precautions for
             90 days after the final dose of treatment; cessation of birth control after this point
             should be discussed with a responsible physician

         20. Males, unless surgically sterile, must use 2 effective methods of birth control with a
             female partner and must agree to continue using such contraceptive precautions from
             screening through 90 days after the final dose of treatment

         21. Normal potassium at baseline

         22. Normal magnesium at baseline

        Exclusion Critieria

        Any of the following would exclude the subject from participation in the study:

          1. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the treatment or interpretation of subject safety or study results

          2. Concurrent enrollment in another clinical study

          3. Employees of the clinical study site or any other individuals involved with the
             conduct of the study, or immediate family members of such individuals

          4. Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal
             therapy for treatment of cancer

          5. Previous mAb treatment specifically directed against PDGF or PDGF receptors

          6. History of serious allergy or reaction to any component of the MEDI-575 formulation

          7. Receipt of any previous systemic anticancer therapies for advanced or metastatic
             disease including chemotherapy regimens, hormonal therapy, TKIs, radiotherapy,
             investigational agents, or any biological or immunological based therapies (including,
             but not limited to mAb therapy such as bevacizumab)

          8. Previous adjuvant/neoadjuvant radiotherapy or chemotherapy for treatment of previous
             nonmetastatic disease is allowed provided that 6 months have elapsed from the end of
             such therapies to the time of enrollment.

          9. New York Heart Association ≥ Class II congestive heart failure (see Appendix 3)
             MedImmune Protocol CD-ON-MEDI-575-1031

         10. History of myocardial infarction, unstable angina, transient ischemic attack or stroke
             within the previous 6 months prior to enrollment

         11. History of other invasive malignancy within 5 years except for cervical carcinoma in
             situ (CIS), nonmelanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS)
             of the breast that have been surgically cured

         12. Evidence of active infection requiring the use of systemic antimicrobial treatment
             within 72 hours prior to initial treatment with MEDI-575

         13. Use of immunosuppressive medication (inhaled and topical corticosteroids are
             permitted) within 7 days prior to enrollment

         14. Systemic immunosuppressive steroid therapy. Subjects may take replacement doses of
             steroids (defined as ≤ 30 mg day hydrocortisone or the equivalent) if on a stable dose
             for at least 2 weeks prior to enrollment

         15. History of active human immunodeficiency virus (HIV) or active hepatitis B virus (HBV)
             or hepatitis C virus (HCV) infection

         16. Pregnancy or lactation

         17. Previous medical history or evidence of an intercurrent illness that may, in the
             opinion of the investigator, compromise the safety of the subject in the study

         18. Clinically significant abnormality on ECG

         19. Any physical, social, or psychiatric condition which would prevent effective
             cooperation or participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naimish Pandya, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dover</city>
        <state>Ohio</state>
        <zip>44622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hilton Head</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mrozy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 7, 2016</submitted>
    <returned>July 15, 2016</returned>
    <submitted>September 29, 2016</submitted>
    <returned>November 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

